Unknown PHASE2 INTERVENTIONAL 2-arm NCT01129739

Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes

Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat RA and RARS of MDS

Sponsor: National Natural Science Foundation of China

Interventions Human umbilical cord-derived MSCs cyclosporine A (CsA)

Updated 6 times since 2017 Last updated: May 24, 2010 Started: May 31, 2010 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01129739, this PHASE2 trial focuses on Myelodysplastic Syndromes and remains ongoing. Sponsored by National Natural Science Foundation of China, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Natural Science Foundation of China
Shandong University

Data source: Shandong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China